In their quest for the next big drug discovery, reports the Springfield, Missouri News-Leader , pharmaceutical companies are increasingly teaming up with some of the nation’s top universities, recruiting campus scientists as partners and offering schools multimillion-dollar deals to work on experimental drugs in development. Dr. Marcia Angell, former editor-in-chief of the New England Journal of Medicine criticized the pharmaceutical industry’s new coziness with major campuses. “What it does,” she said, “is to blur the boundaries between academic medical centers and investor-owned companies”.